Articles From: ARI Network Services Announces Launch of First Mobile App to Arista Networks to Announce Q3 Fiscal Year 2014 Financial Results on Thursday, November 6th


MILWAUKEE, Oct.
Sign-up for ARI Network Services Announces Launch of First Mobile App investment picks
MILWAUKEE, Oct.
Sign-up for ARI's Digital Marketing Services Wins HME Business 2014 New Product Award investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) and Bellicum Pharmaceuticals, Inc. today announced a restructuring of their license agreement for ARIAD’s cell-signaling technology.
Sign-up for ARIAD and Bellicum Announce Revised License Agreement for ARIAD’s Cell-Signaling Technology investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), today announced the marketing approval of Iclusig TM (ponatinib) in Australia by the Therapeutic Goods Administration (TGA). The Australian Product Information for Iclusig states that it is indicated for the treatment of adult patients with: Chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) whose disease is resistant to, or who are intolerant of at least two prior tyrosine kinase inhibitors; or where there is a T315I mutation.
Sign-up for ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted its final opinion on Iclusig ® (ponatinib) following the recommendations made by the Pharmacovigilance Risk Assessment Committee (PRAC) earlier this month.
Sign-up for ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced safety and efficacy follow-up data on Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in patients with a baseline T315I mutation from its Phase 1 and Phase 2 PACE trials in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). With a median follow-up of three years for CP-CML patients and nine months overall, Iclusig continues to exhibit responses in patients with the T315I mutation, for whom there is no other approved tyrosine kinase inhibitor (TKI) therapy.
Sign-up for ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the schedule of several data presentations on Iclusig ® (ponatinib) that will take place at the 56th Annual Meeting of the American Society of Hematology (ASH) being held in San Francisco, December 6 to 9, 2014.
Sign-up for ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced long-term follow up from its pivotal Phase 2 trial of Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of approximately 3 years for chronic-phase CML (CP-CML) patients in the trial, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options.
Sign-up for ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term follow up data from the Phase 1 trial of Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of four years in chronic phase CML (CP-CML) patients, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options and that responses have been maintained in CP-CML patients (n=43) with 72 percent having a major cytogenetic response (MCyR), 65 percent having a complete cytogenetic response (CCyR) and 56 percent having a major molecular response (MMR). Long-term safety data show that careful benefit-risk evaluations should guide decisions to use and maintain
Sign-up for ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has concluded its review of Iclusig ® (ponatinib) under the Article 20 referral procedure and has recommended that Iclusig continue to be used in Europe in accordance with its already approved indications.
Sign-up for ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113 , in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.
Sign-up for ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the third quarter of 2014, including revenue from sales of Iclusig ® (ponatinib). The Company also provided an update on corporate developments.
Sign-up for ARIAD Reports Third Quarter 2014 Financial Results and Development Progress investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Stifel 2014 Healthcare Conference in New York City.
Sign-up for ARIAD to Present at the Stifel 2014 Healthcare Conference investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its third quarter 2014 financial results on Wednesday, November 5, 2014, before the market opens.
Sign-up for ARIAD to Webcast Conference Call on Third Quarter 2014 Financial Results investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its investigational cancer medicine, AP26113 , has received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who are resistant to crizotinib.
Sign-up for ARIAD’s AP26113 Receives FDA Breakthrough Therapy Designation For ALK+ Non-Small Cell Lung Cancer Resistant to Crizotinib investment picks
2014/11/17
The future of business commerce is collaborative, predictive and innovative.
Sign-up for Ariba LIVE 2015: The Future of Commerce investment picks
2014/12/2
Ariba ® Pay ™ is catching fire.
Sign-up for AribaPay Takes Off investment picks
2014/10/22
Arista Networks today announced an expansion of its leaf switch portfolio that includes the highest density leaf switches with integrated optics and high performance, VXLAN support.
Sign-up for Arista Expands Leaf Switch Product Portfolio investment picks
2014/12/10
Arista Networks announced today the addition of EOS+ , a software platform for network programmability and automation as an evolution of Arista EOS (Extensible Operating System). EOS+ provides an advanced level of programmability, allowing customers to take advantage of pre-built and custom EOS applications as well as integration with a wide range of technology partner solutions from A10 Networks , Ansible , Aruba , Cloudera , Nuage , Palo Alto Networks , Puppet Labs , Pure Storage , Red Hat , Splunk , VMTurbo , VMware and Zscaler .
Sign-up for Arista Introduces EOS+: Platform For Software Driven Cloud Networking investment picks
Arista Networks, Inc. (NYSE:ANET) today announced participation in the following events with the financial community: Credit Suisse Technology Conference Kelyn Brannon, CFO Phoenix, AZ Thursday, December 4, 2014 8:30am PT / 11:30am ET Raymond James S4 Conference Kelyn Brannon, CFO New York, NY Monday, December 8, 2014 12:00pm PT / 3:00pm ET Barclays Annual Tech Conference Jayshree Ullal, President and CEO San Francisco, CA Tuesday, December 9, 2014 12:45pm PT / 3:45pm ET Bernstein Emerging Tech Conference Kelyn Brannon, CFO Boston, MA Tuesday, December 16, 2014 8:00am PT / 11:00am ET A live audio webcast of these events will be accessible from the "Investors" section of Arista Networks website at investors.arista.com .
Sign-up for Arista Networks Announces Participation in Upcoming Investor Events for December investment picks
Arista Networks, Inc. (NYSE:ANET) today announced participation in the following events with the financial community: RBC Technology, Internet, Media & Telecom Conference Mark Foss, Vice President, Global Operations and Marketing New York, NY Monday, November 10, 2014 10:30am PT / 1:30pm ET Needham Next-Gen Storage/Networking Conference Mark Foss, Vice President, Global Operations and Marketing New York, NY Tuesday, November 11, 2014
Sign-up for Arista Networks Announces Participation in Upcoming Investor Events for November investment picks
Arista Networks, Inc. (NYSE:ANET) will release its financial results for the quarter ended September 30, 2014 after U.S. markets close on Thursday, November 6 th .
Sign-up for Arista Networks to Announce Q3 Fiscal Year 2014 Financial Results on Thursday, November 6th investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: ARI Network Services Announces Launch of First Mobile App to Arista Networks to Announce Q3 Fiscal Year 2014 Financial Results on Thursday, November 6th
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent